OPTIMA-TBI: A Randomized, Placebo-Controlled Trial of Omega-3 in TBI

Authors: OPTIMA-TBI Study Group

Published: January 1, 1970

An active randomized, placebo-controlled, double-blinded trial testing 6g/day of DHA+EPA for one month followed by 1.2g/day - a high-dose protocol resembling BHERI's saturation approach. Measures biomarkers of neuronal injury, inflammation, and neurogenesis. Represents the rigorous trial work now validating the approach BHERI has applied clinically.